Kaiser Michael A, Ferrari Lina M, Gaumond Simonetta I, Issa Najy, Jimenez Joaquin J, Issa Naiem T
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
St. George's University School of Medicine, West Indies, Grenada.
J Cutan Aesthet Surg. 2023 Jul-Sep;16(3):169-177. doi: 10.4103/JCAS.JCAS_206_22.
Androgenetic alopecia (AGA) is the most common cause of alopecia in males and females. Minoxidil and finasteride are the only FDA-approved treatments for AGA. New treatments including Platelet Rich Plasma (PRP) and microneedling have shown promising results. The purpose of this literature review was to highlight recent studies examining the effects of topical minoxidil combined with PRP to minoxidil or PRP monotherapy. The method used for this paper includes a systematic review of the literature from 2010 to 2022 using the PubMed, EMBASE, and MEDLINE databases examining studies evaluating combination therapies for AGA. Three randomized control trials compared combination PRP + topical 5% minoxidil to either no treatment, 5% minoxidil, or PRP only. Two studies found increased hair growth at five months and at six months following combined therapy. Another study found an increase in hair density and improved patient satisfaction with combination therapy compared to monotherapy. A prospective study revealed that patients treated with combined 5% minoxidil, PRP, and microneedling reported the highest patient and physician satisfaction compared to minoxidil monotherapy. An observational study evaluating topical 5% minoxidil with PRP reported an increase in hair diameter after one year of combination treatment compared to minoxidil monotherapy. PRP therapy combined with minoxidil and microneedling in a retrospective study was shown to increase hair growth compared to PRP with minoxidil as well as PRP or minoxidil monotherapy. In conclusion, a variety of studies demonstrated superior treatment response with a combination of PRP and minoxidil therapy in patients with AGA. Limitations to this study include different PRP preparation protocols, few randomized control studies, and small sample sizes.
雄激素性脱发(AGA)是男性和女性脱发最常见的原因。米诺地尔和非那雄胺是美国食品药品监督管理局(FDA)批准的仅有的两种AGA治疗药物。包括富血小板血浆(PRP)和微针治疗在内的新治疗方法已显示出有前景的效果。这篇文献综述的目的是强调近期研究,这些研究探讨了局部使用米诺地尔联合PRP与米诺地尔或PRP单一疗法相比的效果。本文使用的方法包括对2010年至2022年的文献进行系统综述,通过PubMed、EMBASE和MEDLINE数据库检索评估AGA联合治疗的研究。三项随机对照试验将PRP联合局部5%米诺地尔与不治疗、5%米诺地尔或仅PRP进行了比较。两项研究发现联合治疗后五个月和六个月时头发生长增加。另一项研究发现与单一疗法相比,联合治疗的头发密度增加且患者满意度提高。一项前瞻性研究表明,与米诺地尔单一疗法相比,接受5%米诺地尔、PRP和微针联合治疗的患者报告的患者和医生满意度最高。一项评估局部5%米诺地尔与PRP联合治疗的观察性研究报告称,与米诺地尔单一疗法相比,联合治疗一年后头发直径增加。一项回顾性研究表明,与PRP联合米诺地尔以及PRP或米诺地尔单一疗法相比,PRP疗法联合米诺地尔和微针治疗可增加头发生长。总之,各种研究表明,PRP和米诺地尔联合治疗对AGA患者具有更好治疗反应。本研究的局限性包括不同的PRP制备方案、随机对照研究较少以及样本量较小。